WebOct 5, 2024 · The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are … WebDec 14, 2024 · Chinook Therapeutics, Inc. today announced the European Commission has granted orphan drug designation for atrasentan for the treatment of primary IgA nephropathy (IgAN). ... Chinook expects to present data from the IgAN patient cohort of the phase 2 AFFINITY study in the first half of 2024, with data from one or more additional cohorts ...
Resident orcas’ appetite likely reason for decline of big Chinook ...
WebApr 11, 2024 · SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision ... WebNov 3, 2024 · The AFFINITY Study (see www.clinicaltrials.gov, identifier NCT04573920) is an ongoing global phase 2, open-label, basket study to evaluate the safety and efficacy of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of kidney function. The four AFFINITY cohorts consist of patients with: biopsy-proven ... seed empire
Chinook Therapeutics Presents Data from Atrasentan …
WebSep 28, 2024 · The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function. Cohorts will consist of patients with: IgA nephropathy (IgAN) with urine protein:creatinine ratio (UPCR) of 0.5 to less than 1.0 g/g WebChinook Therapeutics: Changing the Course of Kidney Care . 31 Mar 2024 13:00 14:00. MR 110 ... Session; 13:00. 13:30. Atrasentan for the Treatment of IgA Nephropathy: Interim Results from the AFFINITY Study . Adrian Liew Speaker [email protected] Mount Elizabeth Novena Hospital Singapore. 13:30. 14:00. Updated Interim Results of a Phase … WebApr 7, 2024 · Chinook expects to report data from initial cohorts of patients in the AFFINITY Study during 2024. About Chinook Therapeutics, Inc. Chinook Therapeutics, Inc. is a … seed eating birds uk